← Back to Clinical Trials
Recruiting NCT07201974

NCT07201974 Virtual Reality for Post-Stroke Gait Rehabilitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07201974
Status Recruiting
Phase
Sponsor McGill University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-02-01
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 84 Years
Study Type INTERVENTIONAL
Interventions
Virtual Reality Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-02-01 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to: (1) implement and test the feasibility of a new VR-ODT intervention offered as part of usual therapy time of patients with a sub-acute stoke; (2) explore the acceptability of the intervention from the perspective of clinicians and patients and; (3) implement measures to optimize the uptake and sustainability of the intervention within the clinical setting. Participants will engage in a personalized VR-ODT training for 4 weeks (2X 1hr/week) targeting six well-established community walking demands related to (1) walking speed and (2) distance; (3) postural transitions; (4) obstacle avoidance; (5) dual-task walking and; (6) a combination of demands 1-5. For each demand, patients will progress through levels of increasing difficulty according to personalized goals and success criteria.

Eligibility Criteria

Inclusion Criteria: Eligible patients with stroke referred by clinicians of the inpatient and outpatient stroke rehabilitation programs at the Jewish Rehabilitation Hospital (CISSS Laval) for mobility problems over a period of 6 months will be recruited. They will: * be aged between 40 and 74 years; * have normal/corrected visual and auditory acuity present; * present a first-ever supratentorial unilateral stroke of 1-24 weeks duration; * present the ability to walk independently with/without walking aids for at least 1 min at a speed of 0.4-0.9 m/s; * present intact or mildly affected cognitive function (MoCA scores ≥ 22/30); * present intact to moderately affected visual- perceptual function (positive scores on a max. of 3/6 tasks on the Behavioural Inattention Test). Exclusion Criteria: * Subjects with comorbidities interfering with walking * Subjects with comorbidities interfering with visual perception * Subjects without medical clearance for exercise

Contact & Investigator

Central Contact

Anouk Lamontagne, PhD

✉ anouk.lamontagne@mcgill.ca

📞 450-688-9550

Principal Investigator

Anouk Lamontagne, PhD

PRINCIPAL INVESTIGATOR

McGill University

Frequently Asked Questions

Who can join the NCT07201974 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 84 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07201974 currently recruiting?

Yes, NCT07201974 is actively recruiting participants. Contact the research team at anouk.lamontagne@mcgill.ca for enrollment information.

Where is the NCT07201974 trial being conducted?

This trial is being conducted at Laval, Canada.

Who is sponsoring the NCT07201974 clinical trial?

NCT07201974 is sponsored by McGill University. The principal investigator is Anouk Lamontagne, PhD at McGill University. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology